Comparative effects of duloxetine and desipramine on sleep EEG in healthy subjects
- 306 Downloads
Antidepressants are known to modify human sleep patterns.
Duloxetine is a new antidepressant with a mechanism of action involving reuptake inhibition of both serotonin (5-HT) and norepinephrine (NE). In this study, the effects of two dosing regimens of duloxetine on sleep electroencephalography (EEG) were investigated at steady-state plasma concentrations in young, healthy, male subjects.
Placebo (n=12), desipramine (50 mg BID; n=12) and two regimens of duloxetine (80 mg QD, n=6; or 60 mg BID, n=6) were compared in a randomized, double-blind, three-period crossover study, each treatment being administered from day 1 to day 7. Sleep polygraphic recordings took place at baseline (day −1) and day 6 of each period. The Leeds sleep evaluation questionnaire (LSEQ) was also administered on the morning of day 7.
Both regimens of duloxetine produced a significant increase in the onset latency of REM sleep as well as a significant mean decrease in total REM sleep duration. Desipramine exhibited comparable effects. When compared to placebo, sleep continuity was significantly reduced with desipramine and duloxetine 60 mg BID whereas a significant improvement was observed with duloxetine 80 mg QD. On the LSEQ, duloxetine 80 mg QD produced a significant improvement in the “getting to sleep” subscale compared to placebo, whereas desipramine demonstrated a significant reduction (worsening) in the “quality of sleep” score versus placebo.
The two dose regimens of duloxetine (80 mg QD and 60 mg BID) produced a REM sleep pattern comparable to that of most antidepressant medications. Duloxetine 80 mg QD appeared to exhibit less impact upon sleep quality than duloxetine 60 mg BID in healthy subjects.
KeywordsDuloxetine Desipramine Sleep Polysomnography REM sleep
- Brunello N, Armitage R, Feinberg I, Holsboer-Trachsler E, Leger D, Linkowski P, Mendelson WB, Racagni G, Saletu B, Sharpley AL, Turek F, Van Cauter E, Mendlewicz J (2000) Depression and sleep disorders: clinical relevance, economic burden and pharmacological treatment. Neuropsychobiology 42:107–119CrossRefPubMedGoogle Scholar
- Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, Shaw JL, Thompson L, Nelson DL, Hemrick-Luecke SK, Wong DT (2001) Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 25:871–880CrossRefPubMedGoogle Scholar
- Crismon ML, Trivedi M, Pigott TA, Rush AJ, Hirschfeld RM, Kahn DA, DeBattista C, Nelson JC, Nierenberg AA, Sackeim HA, Thase ME (1999) The Texas medication algorithm project: report of the Texas consensus conference panel on medication treatment of major depressive disorder. J Clin Psychiatry 60:142–156PubMedGoogle Scholar
- Gumnick JF, Nemeroff CB (2000) Problems with currently available antidepressants. J Clin Psychiatry 61(Suppl 10):5–15Google Scholar
- Nelson JC (1998) Synergistic benefits of serotonin and noradrenaline reuptake inhibition. Depress Anxiety 7(Suppl 1):5–6Google Scholar
- Nicholson AN, Pascoe PA (1991) Monoaminergic transmission and sleep in man. In: Idzikowski C, Cowen PJ (eds) Serotonin, sleep and mental disorder. Wrightson Biomedical Publishers, Petersfield, pp 215–226Google Scholar
- Rechtschaffen A, Kales A (1968) A manual of standardized terminology, techniques and scoring system for sleep stages of human subjects. Brain Information Service Brain Research Institute, University of California Los AngelesGoogle Scholar
- Schatzberg AF (1999) Antidepressant effectiveness in severe depression and melancholia. J Clin Psychiatry 60(Suppl 4):14–21Google Scholar
- Seeman R (1993) Receptor tables, volume 2: dissociation constants for neuroreceptors and transporters. SZ Research, TorontoGoogle Scholar
- Staner L, Luthringer R, Macher J-P (1999) Effects of antidepressant drugs on sleep EEG in patients with major depression: mechanisms and therapeutic implications. CNS Drugs 11:49–60Google Scholar
- Thase ME, Detke MJ, Joliat M, Lu Y (2003) Remission in placebo-controlled trials of duloxetine with an SSRI comparator. Presented at the 156th Annual Meeting of the American Psychiatric Association, 22 May 2003Google Scholar
- Winokur A, Reynolds CF III (1994) Overview of effects of antidepressant therapies on sleep. Primary Psychiatry 1:22–27Google Scholar